The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Aortic progression and reintervention in patients with pathogenic variants after a thoracic aortic dissection.
To evaluate aortic disease progression and reintervention after an initial thoracic aortic dissection in pathogenic variant carriers. ⋯ Aggressive aortic root replacement and similar arch management should be considered in pathogenic variant carriers at initial type A aortic dissection repair compared with benign/normal variant carriers.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Multicenter Study Observational StudyImpact of perioperative course during cardiac surgery on outcomes in patients 80 years and older.
To describe the associations among preoperative characteristics, intraoperative and postoperative factors, and mortality and morbidity after open-heart surgery in patients age ≥80 years. ⋯ Our findings emphasize the importance of careful referral regarding the procedural burden for very elderly patients and may provide support for informed patient discussions about prognosis and recovery.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Repeated anatomical pulmonary resection for metachronous ipsilateral second non-small cell lung cancer.
We investigated the surgical outcomes of repeated pulmonary resection for metachronous ipsilateral second non-small cell lung cancer (NSCLC). ⋯ Reanatomical pulmonary resection showed acceptable oncologic outcomes for metachronous ipsilateral second NSCLC. The non-CP procedure was technically challenging; however, both oncologic and surgical results were feasible compared with the CP. This procedure might be a promising novel strategy for properly selected ipsilateral second NSCLC.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Multicenter Study Observational StudyIntermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue.
The COMMENCE trial was conducted to evaluate the safety and effectiveness of an aortic bioprosthesis with novel RESILIA tissue (Edwards Lifesciences, Irvine, Calif). Reports of early noncalcific valve failure resulting from thrombosis or leaflet tears in other valves warrant careful evaluation of early valve performance. ⋯ Safety and hemodynamic performance of this aortic bioprosthesis with RESILIA tissue at 4 years are favorable. This novel tissue does not appear to result in unexpected early thrombosis events or noncalcific structural valve deterioration.